StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
William Blair on Viridian Therapeutic (VRDN): 'We came away from the call incrementally more confident'
June 29, 2026 12:25 PM
William Blair analyst Lachlan Hanbury-Brown reiterated an Outperform rating on Viridian Therapeutic (NASDAQ: VRDN)The analyst comments "On Monday, June 29 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Viridian Therapeutic (VRDN) PT Raised to $43 at Wedbush
June 29, 2026 12:25 PM
4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones
June 29, 2026 9:51 AM
Viridian Therapeutic (VRDN) PT Raised to $40 at Stifel
June 29, 2026 9:50 AM
Wells Fargo Upgrades Viridian Therapeutic (VRDN) to Overweight
June 29, 2026 9:43 AM
Truist Reiterates Buy Rating on Viridian Therapeutic (VRDN) Following Veligrotug's FDA approval
June 29, 2026 9:28 AM
UBS Reiterates Buy Rating on Viridian Therapeutic (VRDN)
June 29, 2026 8:39 AM
Comcast, Viridian Therapeutics jump premarket; Doximity slips
June 29, 2026 7:54 AM
H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)
June 29, 2026 7:09 AM
Form 8-K Viridian Therapeutics, For: Jun 26
June 29, 2026 6:02 AM
Viridian Therapeutic (VRDN) Reiterated at Market Outperform by Citizens: Lumvoa Approved
June 29, 2026 4:47 AM
FDA approves Viridian's Lumvoa for thyroid eye disease
June 26, 2026 6:00 PM
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
June 26, 2026 6:00 PM
Form SCHEDULE 13G Viridian Therapeutics, Filed by: Paradigm Biocapital Advisors LP
June 26, 2026 4:05 PM
